NCT01279629

Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis

Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis

• Status: Suspended
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Glenmark Farmacêutica Ltda · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is: To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis. \- Population: 50 patients will be selected from both sexes, healthy, between 18 and 65 years with a clinical diagnosis of chronic plaque psoriasis with PASI \<20%, according to the criteria of inclusion and exclusion.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).	Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.

Timeline

• Start date: 2011-02-01
• First posted: 2011-01-19
• Last updated: 2011-06-20